JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy
Approaching his 200th day as the new Chief Executive Officer of Lonza, Wolfgang Wienand discussed the company’s plans to exit …
Post
-
-
Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic …
-
IMPACT ovarian cancer capsules authorised in China
IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for Senaparib capsules to treat ovarian cancer. The …
-
Novo Nordisk’s Ozempic named in latest Medicare price negotiations
The US government has unveiled 15 additional drugs that will be covered in the next round of Medicare Part D …
-
Pfizer believes in the metaverse: will healthcare thaw the technology’s winter?
The metaverse has faded from buzzword to buzzkill, and the hype that once gripped industries has been quietly brushed under …
-
HEOR explained: Improving healthcare decisions with real-world evidence
Health economics and outcomes research (HEOR) plays a vital role in healthcare decision-making, ensuring that treatments, drugs, and interventions are …
-
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
The first day of the JP Morgan Healthcare Conference held in San Francisco, California from 13 January to 15 January …
-
Charles River and Akron link to integrate cytokines into cell therapy
Charles River Laboratories and Akron Bio have announced the integration of the latter’s closed system solutions (CSS) liquid cytokines into …
-
FDA beats EMA to most approved new drugs in 2024
The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs …
-
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The chronic obstructive pulmonary disease (COPD) market continues its trajectory of rapid growth, bolstered by significant advancements in biologics and …
-
Leading Sales and Marketing Intelligence Providers and Technology Solutions for the Pharmaceutical Industry
Leading sales and marketing intelligence providers and technology solutions for the pharmaceutical industry: Introduction In the fast-paced world of pharmaceuticals, sales …
-
CDE grants BTD to Innovent’s IBI343 for pancreatic cancer
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to …
-
“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure
WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due …
-
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player …
-
JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix’s busy year
Following a year thick with acquisitions across the radiopharmaceutical supply chain, Telix Pharmaceuticals has announced a 55% year-on-year revenue increase …
